Amplify Weight Loss Drug & Treatment ETF (NY:THNR)

26.45 +0.04 (+0.15%)

Streaming Delayed Price Updated: 11:30 AM EDT, Jul 6, 2026 Add to My Watchlist

Price and Volume

Volume	10,884
Open	26.92
Bid (Size)	26.41 (3,200)
Ask (Size)	26.49 (200)
Prev. Close	26.41
Today's Range	26.30 - 26.92
52wk Range	21.70 - 27.28
Shares Outstanding	1,300
Dividend Yield	1.56%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗

April 17, 2026

Via MarketBeat

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗

February 25, 2026

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

Via Stocktwits

Performance

YTD	+4.0%	+4.0%
1 Month	+8.8%	+8.8%
3 Month	+7.2%	+7.2%
6 Month	+3.7%	+3.7%
1 Year	+16.2%	+16.2%

More News

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance ↗

February 04, 2026

Via Stocktwits

LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗

February 04, 2026

Via Stocktwits

Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill ↗

December 23, 2025

Via Stocktwits

The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In ↗

December 09, 2025

Via Stocktwits

Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗

January 30, 2026

Via Stocktwits

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs ↗

September 18, 2025

Via Benzinga

Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares ↗

December 13, 2024

Via Benzinga

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗

July 18, 2024

Via Benzinga

ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential ↗

June 07, 2024

Via Benzinga

Frequently Asked Questions

Is Amplify Weight Loss Drug & Treatment ETF publicly traded?

Yes, Amplify Weight Loss Drug & Treatment ETF is publicly traded.

What exchange does Amplify Weight Loss Drug & Treatment ETF trade on?

Amplify Weight Loss Drug & Treatment ETF trades on the New York Stock Exchange

What is the ticker symbol for Amplify Weight Loss Drug & Treatment ETF?

The ticker symbol for Amplify Weight Loss Drug & Treatment ETF is THNR on the New York Stock Exchange

What is the current price of Amplify Weight Loss Drug & Treatment ETF?

The current price of Amplify Weight Loss Drug & Treatment ETF is 26.45

When was Amplify Weight Loss Drug & Treatment ETF last traded?

The last trade of Amplify Weight Loss Drug & Treatment ETF was at 07/06/26 11:30 AM ET

What is the market capitalization of Amplify Weight Loss Drug & Treatment ETF?

The market capitalization of Amplify Weight Loss Drug & Treatment ETF is 34.38K

How many shares of Amplify Weight Loss Drug & Treatment ETF are outstanding?

Amplify Weight Loss Drug & Treatment ETF has 34K shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.